CBS 2019
CBSMD教育中心
中 文

Other Relevant Articles

Abstract

Recommended Article

How Low to Go With Glucose, Cholesterol, and Blood Pressure in Primary Prevention of CVD 2017 ACC/AHA Blood Pressure Treatment Guideline Recommendations and Cardiovascular Risk Antithrombotic Therapy in Patients with Atrial Fibrillation and Acute Coronary Syndrome Treated Medically or with Percutaneous Coronary Intervention or Undergoing Elective Percutaneous Coronary Intervention: Insights from the AUGUSTUS Trial Current Perspectives on Coronavirus Disease 2019 and Cardiovascular Disease: A White Paper by the JAHA Editors Impact of lesion complexity on peri-procedural adverse events and the benefit of potent intravenous platelet adenosine diphosphate receptor inhibition after percutaneous coronary intervention: core laboratory analysis from 10 854 patients from the CHAMPION PHOENIX trial Position paper of the EACVI and EANM on artificial intelligence applications in multimodality cardiovascular imaging using SPECT/CT, PET/CT, and cardiac CT De-escalation of antianginal medications after successful chronic total occlusion percutaneous coronary intervention: Frequency and relationship with health status Defining Staged Procedures for Percutaneous Coronary Intervention Trials A Guidance Document

ConsensusNovember 2018

JOURNAL:J Am Coll Cardiol. Article Link

2018 ACC Expert Consensus Decision Pathway on Novel Therapies for Cardiovascular Risk Reduction in Patients With Type 2 Diabetes and Atherosclerotic Cardiovascular Disease A Report of the American College of Cardiology Task Force on Expert Consensus Decision Pathways

Writing Committee, Sandeep RD, Brendan M et al. Keywords: ASCVD; cardiovascular risk reduction; diabetes; Expert Consensus; Decision Pathway; GLP-1RA; SGLT2 inhibitor; T2D

FULL TEXT PDF